0 required post coital and 1 obtained self-start antibiotics 13/25 (52%) women only required 1 appointment with the service and at 12 months 21/25 no longer require any contact (discharge or DNA).
INTRODUCTION AND OBJECTIVES:
UTIs are prevalent worldwide, with incidence increasing with age. Lower oestrogen levels post-menopause leads to the loss of the acidic vaginal defence, thus increasing risks of UTIs. These women often require long-term antibiotics. However the alarming rise of antibiotic resistance worldwide, along with a WHO Global Action Plan combating resistance, provides an urgent need to find viable alternatives.
FemTouch is a thermo-ablative laser which induces a histological rejuvenation of the vaginal lining, with thickened squamous epithelium, glycogen storage and extracellular matrix synthesis, similar to oestrogen therapy. We present the first experience in the United Kingdom of using FemTouch to treat a preliminary cohort of postmenopausal women with recurrent UTIs.
METHODS: 12 post-menopausal women with recurrent UTIs received 3 courses of FemTouch treatment at monthly intervals. Prior to treatment, all women underwent a cervical smear for cytology and MC&S. Subsequent follow-up for up to 12 months post first treatment assessed rates of UTI, changes in vaginal pH and vaginal health. No concurrent antibiotic or hormonal therapy was used throughout.
RESULTS: 9/12 (75%) of women were UTI free in the 12 months follow up. 1 patient had first recurrence at 6 months. 2 further patients had UTI recurrences at month 9. Vaginal acidity improved from pH 7.0 pretreatment to pH 5.4 at 6 months, rising to pH 6.2 by 12 months. Vaginal Health Index Score showed improvement from 11 ( 15 is deemed atrophic) pre-treatment to 20 at 3 months and 19 at 6 months. By 12 months this had decreased to 15. All patients completed treatment and described the "pain" of the procedure as 1/10 on average.
CONCLUSIONS: These initial results suggest that FemTouch is both effective and safe in postmenopausal women with recurrent UTIs and may be a potentially viable alternative to antibiotic prophylaxis. FemTouch also greatly restored vaginal conditions out of the atrophic state. The positive benefits with FemTouch treatment appears to start wearing off by 12 months, suggesting a further course may be needed on a yearly basis. Our preliminary results supports creating an international multi-centre trial to further investigate FemTouch in larger groups of patients with longer follow-up periods.
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MP71-19 ROLE OF VACCINES FOR RECURRENT URINARY TRACT INFECTIONS: A SYSTEMATIC REVIEW
Sarah Prattley*, Francesca New, Rob Geraghty, Bhaskar Somani, Southampton, United Kingdom INTRODUCTION AND OBJECTIVES: Recurrent urinary tract infections (rUTIs) can be difficult to treat although there are some nonantibiotic therapies it is not always clinically efficacious. We therefore conducted a systematic review to look at the available evidence on the use of vaccines for recurrent UTIs.
METHODS: A systematic review was conducted for all English language articles identified by a literature search of EMBASE, CINAHL, MEDLINE, Scopus, Biomed Central, and Web of Science between inception and July 2018. Data extraction was carried out independently by two authors for patient demographics, vaccine type, method of administration, bacterial content, efficacy, adverse events, discontinuation and follow-up.
RESULTS: After initial identification of 168 studies, 36 abstracts were screened, 25 full articles were assessed, and 19 studies were included for final review. A total of 3,275 patients, 2,019 patients in the vaccine group and 1,256 patients in the control/antibiotic/placebo/ observational group were included (from 19 studies) reviewing 4 different vaccine types (Uromune, UroVaxom, Solco-Urovac and ExPEC4V). There were 3 studies in Uromune (n[ 594 patients), 11 in UroVaxom (n [ 1,176 patients), 4 in Solco-Urovac (n[ 157 patients) and 1 in ExPEC4V (n[ 92 patients) groups.
The overall efficacy for UTI free rates across all vaccines varied from 22.2% to 87.5%, and 52% to 90.3% over 3-6 months and 6-12 months respectively. Discontinuation due to potential adverse reaction was only reported in 13 cases of vaccination across all studies. The adverse events were Clavien I and varied from 4.4% to 13% across studies with the most frequent being gastrointestinal upset, pain at injection site and vaginal irritation, depending on vaccine used. CONCLUSIONS: Our review suggests that vaccines have a promising role in the prevention of recurrent UTIs over a short-term period of up to 12 months. Although the clinical efficacy is good with a low risk of morbidity, further long-term follow-up studies will be required before they can be routinely used in clinical practice.
